Novocure’s Optune Gio fails to show benefit at earlier stage
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit…
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit…
Following news that started brewing last week, Dr Marty Makary has officially resigned from his post as commissioner of the…
CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated…
One of the main challenges for medical device developers is ensuring clinical trials meet the expectations of all regulatory authorities…
US President Donald Trump's 200% tariff threat on the pharmaceutical industry is a "shock" that will reverberate through global supply…
US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer therapy more tolerable. The…
Experts are emphasising that safeguarding patient data from corporations and cyberattacks is vital for the NHS to create a single…
European residents must be fully informed to properly trust the incoming European Health Data Space (EHDS) regulation if it is…
BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory…
With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics.…